Reply to: Comments on "An open-label randomised-controlled trial of azathioprine vs. mycophenolate mofetil for the induction of remission in treatment-naive autoimmune hepatitis"

Affiliations

¹ Department of Gastroenterology and Hepatology, Radboudumc, Nijmegen, the Netherlands; European Reference Network on Hepatological Diseases (ERN RARE-LIVER), Germany. Electronic address: Romee.Snijders@radboudumc.nl.
² Department of Gastroenterology and Hepatology, Leiden University Medical Centre, Leiden, The Netherlands.
³ Department of Gastroenterology and Hepatology, Amsterdam University Medical Centres, Amsterdam, The Netherlands; European Reference Network on Hepatological Diseases (ERN RARE-LIVER), Germany.

Comment

Romée J A L M Snijders et al. J Hepatol. 2024 Jul.

. 2024 Jul;81(1):e43-e44.

doi: 10.1016/j.jhep.2024.03.038. Epub 2024 Mar 28.

¹ Department of Gastroenterology and Hepatology, Radboudumc, Nijmegen, the Netherlands; European Reference Network on Hepatological Diseases (ERN RARE-LIVER), Germany. Electronic address: Romee.Snijders@radboudumc.nl.
² Department of Gastroenterology and Hepatology, Leiden University Medical Centre, Leiden, The Netherlands.
³ Department of Gastroenterology and Hepatology, Amsterdam University Medical Centres, Amsterdam, The Netherlands; European Reference Network on Hepatological Diseases (ERN RARE-LIVER), Germany.

No abstract available

Comment on

Mycophenolate mofetil for the induction of remission in primary biliary cholangitis with predominant features of autoimmune hepatitis.
Fan X, Yang F, Zhou L, Yang L. Fan X, et al. J Hepatol. 2024 Jul;81(1):e35-e36. doi: 10.1016/j.jhep.2024.01.020. Epub 2024 Feb 1. J Hepatol. 2024. PMID: 38307344 No abstract available.
From the experimental to the clinical: Deepening the understanding of mycophenolate mofetil combined with prednisolone therapy.
Xu Y, Yu X, Guo Y. Xu Y, et al. J Hepatol. 2024 Jul;81(1):e37. doi: 10.1016/j.jhep.2024.02.007. Epub 2024 Feb 10. J Hepatol. 2024. PMID: 38346578 No abstract available.
Autoimmune hepatitis: Azathioprine or mycophenolate mofetil for inducing remission?
Tiwari A, Khanikar D, Rathod SG. Tiwari A, et al. J Hepatol. 2024 Jul;81(1):e38-e39. doi: 10.1016/j.jhep.2024.02.012. Epub 2024 Feb 23. J Hepatol. 2024. PMID: 38403031 No abstract available.
Should MMF treatment be the first-line therapy in autoimmune hepatitis?
Alric L. Alric L. J Hepatol. 2024 Jul;81(1):e40. doi: 10.1016/j.jhep.2024.02.014. Epub 2024 Feb 23. J Hepatol. 2024. PMID: 38403032 No abstract available.
Autoimmune hepatitis: Mycophenolate mofetil vs. azathioprine as first-line therapy.
Şimşek C, Wahlin S, Efe C. Şimşek C, et al. J Hepatol. 2024 Jul;81(1):e41-e42. doi: 10.1016/j.jhep.2024.02.022. Epub 2024 Mar 6. J Hepatol. 2024. PMID: 38458322 No abstract available.